Terlipressin. Type I hepatorenal syndrome: an extra window of time before liver transplantation.
In some patients with type I hepatorenal syndrome, a retrospective study suggests, albeit with a low level of evidence, that terlipressin increases survival time by about a week, which sometimes allows enough time to find a suitable liver donor. Adverse effects due to the vasoconstrictive action of terlipressin require close monitoring during treatment.
D002986:Clinical Trials as Topic; D005602:France; D006530:Hepatorenal Syndrome / Q000188:drug therapy*; D006801:Humans; D008236:Lypressin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D013534:Survival; D013997:Time Factors; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D014662:Vasoconstrictor Agents; D008236:Lypressin